Controlled release formulations using intelligent polymers

Abstract

A controlled release pharmaceutical composition comprises (a) at least one pharmaceutically active substance having a water contact angle (θ) such that cos θ is between +0.9848 and −0.9848, (b) a first intelligent polymer component; and (c) a second intelligent polymer component having opposite wettability characteristics to the first intelligent polymer component, the first and second polymer components being present in a ratio in the range of about 1:100 to about 100:1 by weight. The polymer components are effective for controlled release of the pharmaceutically active substance from the composition.

Description

FIELD OF THE INVENTION [0001] The present invention is directed to novel controlled release formulations of pharmaceutically active substances and methods for their preparation. More particularly, the present invention relates to an easily absorbable, controlled release pharmaceutical formulation utilizing groups of intelligent polymers having opposing wettability characteristics. BACKGROUND OF THE INVENTION [0002] Controlled release formulations of pharmaceutical agents is an extremely large market in the pharmaceutical and medical fields. A number of types of controlled release dosage forms are known, including matrix tablet systems incorporating active ingredients, fillers and various types of excipients. The very different properties of numerous different types of pharmaceutically active ingredients has necessitated the development of a number of different drug delivery systems utilizing polymer technology in order to provide an appropriate release of a particular medicament aft...

AI Technical Summary

Benefits of technology

[0021] An object of the present invention is to provide a novel controlled sustained release delivery composition which may contain a wide variety of pharmaceutically active ingredients and which demonstrates good absorbability of the selected active ingredient and a maintenance of the therapeutically effective blood level of the pharmaceutically active ingredient for a long duration of time by one time administration. This novel controlled release composition and system has been named intelliGITransporter™.

[0024] It is still further objective of the present invention to provide a controlled release delivery composition wherein the selection of the pharmaceutically active ingredient, the physiochemical properties, the proportion of polymer blend and the wettability of the pharmaceutically active substance(s) provides effective controlled release of the pharmaceutically active substance(s).

[0025] It is yet a further object of the present invention to provide an effective drug delivery composition that is capable of controlled drug delivery of both high dose, highly soluble hydrophilic or low dose poorly soluble hydrophobic pharmaceutically active substance(s) to the gastrointestinal tract with a zero or first order kinetics.

[0026] In accordance with a further object of the present invention is a device for providing a controlled release of a pharmaceutically active ingredient contained therein, the device comprising at least one selected pharmaceutically active ingredient incorporated within a homogeneous matrix comprising effective amounts of two intelligent polymers having opposing wettability characteristics, wherein one polymer is selected which demonstrates a stronger tendency towards hydrophobicity and the other polymer is selected which demonstrates a stronger tendency towards hydrophilicity.

[0027] The composition and device of the present invention can be provided as a tablet and may be optionally encased in a coating material which prevents the burst and / or food effect associated with orally ingested medicaments and imparts gastrointestinal stealth characteristics. The encoated matrix providing controlled release kinetics comparable to those of osmotic or press coated controlled release devices. The composition may be provided for oral administration or as a suppository depending on the chosen pharmaceutical active agent selected therein.

Problems solved by technology

While these systems can provide for sustained release of a selected active ingredient, most of these systems have the disadvantage of being affected by the presence of food and gastrointestinal enzymes in the gastrointestinal (GI) tract.

Therefore, the active ingredient is often not delivered in a consistent and reproducible manner.

In addition, osmotic and press coated tablets are particularly difficult and expensive to manufacture.